SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $19,955,238,553 |
| Positions | 84 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| Incyte Corporation | INCY | COM | $3,487,217,729 | 30,762,330 |
| BeOne Medicines Ltd. | ONC | SPONSORED ADS | $2,508,182,548 | 8,801,567 |
| Revolution Medicines, Inc. | RVMD | COM | $2,143,111,899 | 11,443,357 |
| Madrigal Pharmaceuticals, Inc. | MDGL | COM | $1,150,754,190 | 2,143,131 |
| ACADIA Pharmaceuticals Inc. | ACAD | COM | $1,085,696,471 | 42,912,904 |
| Kymera Therapeutics, Inc. | KYMR | COM | $992,725,940 | 8,657,242 |
| Insmed Incorporated | INSM | COM PAR $.01 | $937,841,355 | 8,796,111 |
| Celcuity Inc. | CELC | COM | $828,150,159 | 7,915,792 |
| Kodiak Sciences Inc. | KOD | COM | $776,051,487 | 19,919,186 |
| Rhythm Pharmaceuticals, Inc. | RYTM | COM | $622,265,747 | 5,604,483 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.